FGP
RARE icon

Freestone Grove Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Freestone Grove Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.1K Buy
+1,861
New +$46.2K ﹤0.01% 862
2025
Q4 		– Sell
-18,639
Closed -$561K – 904
2025
Q3 		$561K Buy
+18,639
New +$559K ﹤0.01% 519

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Freestone Grove Partners's RARE Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2026: 1,861 shares worth $62.1K. The stake represents ﹤0.01% of the portfolio and ranks #862 among its holdings. This is a return to the name: Freestone Grove Partners previously reported a position in RARE as recently as Q3 2025.

Freestone Grove Partners first reported a position in RARE in Q3 2025 and has held it in 2 quarters since. The position peaked at $561K in Q3 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Freestone Grove Partners held 1,861 shares of Ultragenyx Pharmaceutical worth $62.1K as of Q2 2026.
  • Ultragenyx Pharmaceutical was a new Freestone Grove Partners position in Q2 2026.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #862 holding.
  • Freestone Grove Partners first reported a position in Ultragenyx Pharmaceutical in Q3 2025 and has held it in 2 quarters since.
  • Freestone Grove Partners's Ultragenyx Pharmaceutical position peaked at $561K in Q3 2025.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.